Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Severe eosinophilic asthma
Severe asthma is a complex heterogeneous disease affecting up to 10% of people with asthma.1 Depending on criteria used, 20% to 79% of patients with severe asthma have been reported as having eosinophilic inflammation 23
30–40% of patients with severe asthma require regular use of OCS 45which can result in serious and often irreversible adverse effects, including bone fractures, cataracts, bruising, muscle weakness, weight gain, cardiovascular complications and infections.678
Meet the types of patients who could benefit from Nucala
Click on the patient type you would like to know more about.
Unless otherwise noted, patient images and cases are for illustrative purposes only.
Sara, age 50, has been living with asthma for the past 15 years.
After experiencing two severe exacerbations last year, Sara has been constantly worried that it might happen again. Her fear has led to her giving up the one activity she loves most, swimming with her friends.
See also:
Firas was diagnosed with asthma seven years ago when he was 32.
Firas is concerned about taking OCS long-term. His confidence took a hit after gaining weight due to the high dose of steroids. He thought he would at least start feeling better, but now his asthma is uncontrolled again. He feels like it has all been for nothing.
See also:
Eman was diagnosed with asthma in her mid-20s; she is now 67. She has had three exacerbations in the last year, requiring hospital stays and oral steroids.
Eman has noticed a dramatic worsening of her asthma over the past year or so. She knows how important it is to keep active as she gets older, but since suffering a severe attack while out with friends a few months ago. Eman prefers not to go too far from home.
See also:
Abeer is 12 and was diagnosed 5 years ago. She had 2 exacerbations in the last year, one of which led to an ED visit.
After these attacks, Abeer missed school and her mother missed work in order to look after her. She hates having asthma attacks and gets very low, especially about missing out on things with her friends.
See also:
BID, twice daily; FEV1, forced expiratory volume in 1 second; OD, once daily; OCS, oral corticosteroid.
Indication:
NUCALA is indicated as add-on maintenance treatment of severe eosinophilic asthma in patients 6 years and older.
Dosage:
Adults and Adolescents (12 years and older)
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
Children aged 6 to 11 years old:
Children weighing ≥ 40 kg
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
Children weighing < 40 kg
The recommended dose is 40 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.
Each vial of NUCALA should be used for a single patient, and any remainder of the vial should be discarded.
References:
- Moore WC, et al. J Allergy Clin Immunol 2007; 119:405-413.
- de Carvalho-Pinto RM, et al. Respir Med. 2012;106:47–56
- Albers FC, et al. J Asthma. 2018;55:152–160
- The ENFUMOSA Study Group. Eur Respir J. 2003;22:470–477;
- Heaney LG, et al. Thorax. 2010;65:787–794;
- Walsh LJ, et al. Thorax. 2001;56:279–284;
- Lefebvre P, et al. J Allergy Clin Immunol. 2015;136:1488–1495;
- Sarnes E,et al. Clin Ther. 2011;33:1413–1432.
- Local Nucala Prescribing Information based on GDS 12.
- Ortega HG et al. Lancet Respir Med 2016; 4:549–556.
Nucala is registered trademark of the GlaxoSmithKline Group of Companies
Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 9
